296 related articles for article (PubMed ID: 34175687)
1. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function.
Gao L; Wu ZX; Assaraf YG; Chen ZS; Wang L
Drug Resist Updat; 2021 Jul; 57():100770. PubMed ID: 34175687
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor genes associated with drug resistance in ovarian cancer (review).
Yin F; Liu X; Li D; Wang Q; Zhang W; Li L
Oncol Rep; 2013 Jul; 30(1):3-10. PubMed ID: 23660957
[TBL] [Abstract][Full Text] [Related]
3. Surmounting cancer drug resistance: New insights from the perspective of N
Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.
Ward A; Shukla K; Balwierz A; Soons Z; König R; Sahin O; Wiemann S
J Pathol; 2014 Aug; 233(4):368-79. PubMed ID: 24752803
[TBL] [Abstract][Full Text] [Related]
5. Distinct and competitive regulatory patterns of tumor suppressor genes and oncogenes in ovarian cancer.
Zhao M; Sun J; Zhao Z
PLoS One; 2012; 7(8):e44175. PubMed ID: 22952919
[TBL] [Abstract][Full Text] [Related]
6. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
[TBL] [Abstract][Full Text] [Related]
7. Towards the overcoming of anticancer drug resistance mediated by p53 mutations.
Cao X; Hou J; An Q; Assaraf YG; Wang X
Drug Resist Updat; 2020 Mar; 49():100671. PubMed ID: 31841768
[TBL] [Abstract][Full Text] [Related]
8. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
[TBL] [Abstract][Full Text] [Related]
9. The multi-factorial nature of clinical multidrug resistance in cancer.
Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH
Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties.
Alhosin M; Sharif T; Mousli M; Etienne-Selloum N; Fuhrmann G; Schini-Kerth VB; Bronner C
J Exp Clin Cancer Res; 2011 Apr; 30(1):41. PubMed ID: 21496237
[TBL] [Abstract][Full Text] [Related]
11. Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy.
Xu JH; Hu SL; Shen GD; Shen G
Cancer Cell Int; 2016; 16():13. PubMed ID: 26900348
[TBL] [Abstract][Full Text] [Related]
12. Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview.
Wang LH; Wu CF; Rajasekaran N; Shin YK
Cell Physiol Biochem; 2018; 51(6):2647-2693. PubMed ID: 30562755
[TBL] [Abstract][Full Text] [Related]
13. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
14. Oncogenes and tumor suppressor genes: comparative genomics and network perspectives.
Zhu K; Liu Q; Zhou Y; Tao C; Zhao Z; Sun J; Xu H
BMC Genomics; 2015; 16 Suppl 7(Suppl 7):S8. PubMed ID: 26099335
[TBL] [Abstract][Full Text] [Related]
15. Physiological modulation approaches to improve cancer chemotherapy : a review.
Kumar R; Kaur M; Silakari O
Anticancer Agents Med Chem; 2014 Jun; 14(5):713-49. PubMed ID: 24117110
[TBL] [Abstract][Full Text] [Related]
16. Concordance of copy number loss and down-regulation of tumor suppressor genes: a pan-cancer study.
Zhao M; Zhao Z
BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):532. PubMed ID: 27556634
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance to chemotherapy in non-small cell lung cancer.
Min HY; Lee HY
Arch Pharm Res; 2021 Feb; 44(2):146-164. PubMed ID: 33608812
[TBL] [Abstract][Full Text] [Related]
18. New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment.
Chen SH; Chang JY
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450627
[TBL] [Abstract][Full Text] [Related]
19. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of tumor cell resistance to the current targeted-therapy agents.
Khamisipour G; Jadidi-Niaragh F; Jahromi AS; Zandi K; Hojjat-Farsangi M
Tumour Biol; 2016 Aug; 37(8):10021-39. PubMed ID: 27155851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
